Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
(SANN) Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of ...
How does this partnership compare to Santhera's existing agreements in other regions and impact its competitive positioning against other DMD therapies?
What is the expected timeline for commercial launch, pricing strategy, and market size for Vamorolone in India?
How will the exclusive distribution agreement in India affect Santhera's revenue forecasts and earnings guidance?
3 days ago